LIPIDOR AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0042 EUR | 0.00% |
|
+2,000.00% | -87.20% |
| 05-22 | Lipidor AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-22 | Lipidor AB Postpones the Publication of Annual Report for 2023 | CI |
| Sales 2022 | 292K 27.69K 25.33K 37.89K | Sales 2023 | 87K 8.25K 7.55K 11.29K | Capitalization | 14.6M 1.39M 1.27M 1.9M |
|---|---|---|---|---|---|
| Net income 2022 | -41M -3.89M -3.56M -5.32M | Net income 2023 | -11M -1.04M -954K -1.43M | EV / Sales 2022 | 42.5 x |
| Net cash position 2022 | 8.93M 847K 774K 1.16M | Net cash position 2023 | 103K 9.77K 8.93K 13.37K | EV / Sales 2023 | 167 x |
| P/E ratio 2022 |
-0.52
x | P/E ratio 2023 |
-1.27
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.17% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +2,000.00% | ||
| Current month | +5.00% | ||
| 1 month | -27.59% | ||
| 3 months | -77.66% | ||
| 6 months | -86.45% | ||
| Current year | -87.20% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.07
1 year
0.000.13
3 years
0.001.25
5 years
0.001.57
10 years
0.001.57
| Managers | Title | Age | Since |
|---|---|---|---|
Ola Holmlund
CEO | Chief Executive Officer | 55 | 17-12-31 |
Jan Holmbäck
FOU | Founder | 67 | 08-12-31 |
Charlotta Ekman
DFI | Director of Finance/CFO | 43 | 22-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 18-12-31 |
Denis Angioletti
BRD | Director/Board Member | 56 | 19-12-31 |
Ola Flink
BRD | Director/Board Member | 80 | 16-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.0042 | 0.00% |
| 24-07-16 | 0.0042 | 0.00% |
| 24-07-15 | 0.0042 | +5.00% |
| 24-07-12 | 0.004 | -4.76% |
| 24-07-11 | 0.0042 | +2,000.00% |
Delayed Quote Deutsche Boerse AG, July 17, 2024 at 03:46 am
More quotes
Lipidor AB is a Sweden-based drug delivery company focusing on topical medication. The Company is focused to develop, patent and commercialize formulation concepts and technologies based on lipids. The Company develops product concepts based on AKVANO technology, which represents a dosage form that creates a lipid layer on the skin surface for effective delivery of drugs and skin care treatment. The Companyâs cooperation partners include Cerbios-Pharma, which specializes in the development and manufacturing of chemical and biological active pharmaceutical ingredients (APIs), and Aurena Laboratories AB, a manufacturer of bag-on-valve aerosol sprays for the pharmaceutical and medical device industry.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +57.56% | 848B | |
| +31.64% | 627B | |
| -0.47% | 363B | |
| +15.44% | 318B | |
| +12.51% | 299B | |
| +15.51% | 243B | |
| +16.72% | 225B | |
| +16.25% | 179B | |
| +3.44% | 167B |
- Stock Market
- Equities
- LIPI Stock
- L7R Stock
